Substance Misuse To Psychiatric Disorders for Cannabis

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Collaborator: Queen Mary Hospital, Hong Kong
• Treatments: Vortioxetine

Criteria

Inclusion Criteria:

• Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive cannabis test results in 1 month with anxiety or depressive symptoms

Exclusion Criteria:

• Age <16 years old

• Unable to read English or Chinese

• Unable to give informed consent

• Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation

• Had history of primary psychotic episode

• Had been diagnosed to have substance-induced mood disorder, other than cannabis

• Had been diagnosed to have mood disorders or anxiety disorders

• Had been taking maintenance therapeutic dose of antidepressant continuously >= 6 months AND with depressive symptom or anxiety symptom being in remission

• Had known hypersensitivity to vortioxetine

• Had known history of serotonin syndrome

• Pregnant

• Mother currently breast-feeding

• Currently taking warfarin and/or having poorly controlled bleeding disorder

• Had history of prolonged QTc ≥500ms and/or known unstable or untreated cardiology disease